Group 1 - The core viewpoint of the news highlights the ongoing volatility in the innovative drug sector, with a mixed performance among individual stocks, while some companies like Kangzhe Pharmaceutical and Green Leaf Pharmaceutical show resilience with over 1% gains [1] - The recent release of the "dual directory" for medical insurance and commercial insurance includes 114 new drugs for the national medical insurance drug list by 2025, with 50 being class 1 innovative drugs, indicating a sustained bullish trend for innovative drugs [3] - CITIC Construction Investment Securities notes that China's pharmaceutical industry has entered a critical phase of "innovation realization + global layout," supported by population and domestic demand, with innovative drugs expected to be a major upward trend into 2026 [3] Group 2 - The Hong Kong Stock Connect Innovative Drug ETF (520880) has over 70% of its portfolio invested in leading innovative drug stocks, reflecting strong buying sentiment despite a slight decline in its market price [1][3] - The top ten holdings of the ETF account for 72.57% of its total weight, showcasing the dominance of leading companies in the innovative drug sector [3] - The ETF has a total market value of HKD 12.873 billion, with a daily average trading volume of HKD 4.58 billion since its inception, making it the largest and most liquid ETF tracking the same index [3]

Group 1 - The core viewpoint of the article highlights the ongoing volatility in the innovative pharmaceutical sector, with a mixed performance among individual stocks, while some, like Kangzhe Pharmaceutical and Green Leaf Pharmaceutical, have seen gains of over 1% [1][7] - The Hong Kong Stock Connect Innovative Pharmaceutical ETF (520880) has over 70% of its holdings in leading innovative pharmaceutical stocks, despite a current price drop of 1.08%, indicating strong buying interest as evidenced by a premium rate exceeding 0.5% [1][7] - The recent release of the dual directory for medical insurance and commercial insurance on December 7, 2023, includes 114 new drugs in the national medical insurance drug list for 2025, with 50 classified as Class 1 innovative drugs and 19 entering the commercial insurance innovative drug directory [1][8] Group 2 - Analysts suggest that the innovative pharmaceutical market is expected to continue its upward trend, remaining a key focus within the pharmaceutical sector, with significant investment safety margins and return potential [3][9] - CITIC Securities indicates that the Chinese pharmaceutical industry has entered a critical phase of "innovation realization + global layout," supported by population and domestic demand, as well as comprehensive manufacturing capabilities [3][9] - The Hong Kong Stock Connect Innovative Pharmaceutical ETF (520880) is recommended as a primary investment vehicle, with its underlying index, the Hang Seng Hong Kong Stock Connect Innovative Pharmaceutical Select Index, showcasing three unique advantages: comprehensive coverage of innovative drug companies, significant weight in leading firms, and better risk control through reduced weight on less liquid stocks [9][10] Group 3 - As of November 30, 2023, the Hong Kong Stock Connect Innovative Pharmaceutical ETF has a scale of 2.142 billion yuan, with an average daily trading volume of 458 million yuan, making it the largest and most liquid ETF tracking the same index [5][10] - The top ten constituent stocks of the ETF account for 72.57% of its total weight, highlighting the dominance of leading innovative pharmaceutical companies [10] - The ETF's structure is designed to exclude CXO companies, focusing solely on pure innovative drug firms, thereby enhancing its appeal to investors seeking exposure to this sector [4][9]

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology sector, with a focus on companies with strong R&D capabilities and commercialized innovative drug products [4][26]. Core Insights - The first commercial health insurance innovative drug directory has been released, which is expected to continuously expand the payment space for innovative drugs [2][21]. - The new basic medical insurance directory includes 127 products, with a success rate of 88% in negotiations, marking the highest success rate in nearly seven years [2][21]. - The commercial health insurance directory includes 24 drugs, with 19 successfully included, focusing on CAR-T and treatments for rare diseases and Alzheimer's [2][22]. - The report emphasizes the importance of clinical value in the pharmaceutical sector, suggesting that investments should focus on innovative drug chains and high-end medical devices [3][24]. Summary by Sections Market Review - The A-share pharmaceutical and biotechnology index fell by 1.17%, underperforming the CSI 300 index by 2.44 percentage points [1][16]. - The H-share Hang Seng Medical Health Index decreased by 0.71%, lagging behind the Hang Seng Index by 1.45 percentage points [1][16]. R&D Progress - Recent IND applications include Yifang Biotech's D-0502 and Hengrui Medicine's HRS-6257 [1][29]. - Clinical trials are ongoing for several drugs, including Shijiazhuang Pharmaceutical's SYS6002 and Zai Ding Pharmaceutical's Aigamod α [1][30]. Key Company Predictions and Valuations - The report provides earnings per share (EPS) forecasts and price-to-earnings (PE) ratios for key companies, recommending a "Buy" for companies like Innovent Biologics and WuXi AppTec [4][26]. Important Updates - The report highlights significant updates from various companies, including strategic partnerships and new product registrations [28][29]. Financial Data - Basic medical insurance revenue reached 2,108.6 billion yuan in the first nine months of 2025, with a monthly income of 227.6 billion yuan in September [33][38]. - The pharmaceutical manufacturing industry saw a revenue decline of 2.90% year-on-year for the first ten months of 2025 [47]. Policy and Market Trends - The report discusses the structural shift in domestic policies favoring innovative drugs and the impact of global economic conditions on the pharmaceutical sector [24][25].

Core Viewpoint - The National Healthcare Security Administration (NHSA) has released the new basic medical insurance drug list for 2025, which will take effect on January 1, 2026, leading to a significant increase in the success rate of new drug negotiations, particularly for innovative drugs with high clinical value [1][2]. Group 1: New Drug Negotiation Success - The success rate for new drug negotiations in 2025 has significantly improved to 88%, up from 76% in 2024, with 114 new drugs added to the national medical insurance drug list, including 50 Class 1 innovative drugs [2][3]. - The total number of drugs in the national medical insurance drug list has increased to 3,253, enhancing coverage for critical areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [2]. Group 2: Unique Drug Inclusion - Among the 114 newly added drugs, 105 are unique varieties, representing 92.11% of the total, including 98 Western medicines and 7 traditional Chinese medicines [3]. - The inclusion of unique traditional Chinese medicines from companies like China Resources Sanjiu, Yiling Pharmaceutical, and others indicates a balanced representation in the new drug list [3]. Group 3: Market Potential and Growth - The inclusion of 116 drugs in the latest negotiation, particularly 11 new drugs from Heng Rui Medicine and others, is expected to lead to rapid market share growth and product volume increase due to their entry into the medical insurance directory [4][5]. - The negotiation also included new mechanism drugs, such as antibody-drug conjugates and small nucleic acid siRNA drugs, which are anticipated to drive market penetration and accessibility [5]. Group 4: Commercial Health Insurance Directory - The first commercial health insurance innovative drug directory saw intense competition, with 121 candidates but only 24 entering negotiations, resulting in 19 drugs being successfully included [6]. - The directory covers critical diseases such as Alzheimer's and multiple myeloma, with a balanced mix of imported and domestic drugs [6]. Group 5: Investment Recommendations - Companies with a significant number of innovative drugs included in the new medical insurance directory, such as Heng Rui Medicine, BeiGene, and others, are recommended for investment [9]. - Potential growth in traditional Chinese medicine products included in the new directory, such as those from China Resources Sanjiu and Yiling Pharmaceutical, is also highlighted [9].

| 分时 5日 = 5分 15分 30分 60分 图K 周K 月K 年K = | | (x = 其他 · ■ / : 恒生指数 (HSI) | | | | | | --- | --- | --- | --- | --- | --- | --- | | 恒生頻數 但因 · | | 0000 | | 26103.08 103.08 | | | | | -27381.84 | | 呼撞报价 | | | | | | | 27000.0 | 域交量 | 7.46亿 新闻 | 2011133 今天 | 26067.86 | | | | | 成交租 | 196亿 最低 | 26067.04 作者 | 20005.06 | | | | 26500.0 | 其他指数 | | | | | | | | 名称 | | 最新 | 双4 | | | | | 周无脂数 | | 58.92 | -0.08% | | | | | 10.05 | | 47264 0 | +0.22 | | | | 25500.0 | 解解达真 | | 21570.12 | +0.31 | | | | | 标值500 | | 6870,40 | +0.137 | ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 港股速报 | 港股小幅高开 内资券商股全线上扬 12月8日早盘，港股市场小幅高开。 截至发稿，恒生指数报26103.08点，上涨18点，涨幅0.07%。 上周末，证监会主席吴清发表重要致辞，围绕"十五五"时期证券行业的使命责任、一流投资银行与投资机构建设两大核心议题，系统提出9条关键要求。吴 清指出，"十五五"是推进中国式现代化、加快建设金融强国的关键时期，证券行业作为直接融资的主要"服务商"、资本市场的重要"看门人"、社会财富的专 业"管理者"，发展空间广阔、大有可为，必须主动呼应时代召唤，自觉担负四大使命责任。 恒生科技指数报5690.54点，上涨28.08点，涨幅0.50%。 焦点板块方面，受消息面刺激，今日内资券商股全线上扬。 今日早盘表现来看，宏业期货（HK03678）大涨超8%，国泰海通（HK02611）、华泰证券（HK06886）涨超5%，中信证券、招商证券、国联民生涨超4%， 其余内资券商股涨幅在2%~4%区间。ETF方面，香港证券ETF早盘涨超3%。 其他方面，盘面上，科网股涨跌不一，百度涨超4%，美团涨超1%、联想跌 ...

Core Viewpoint - The Hong Kong stock market showed a slight increase, with the Hang Seng Index rising by 0.07% to 26,103.08 points, reflecting a positive market sentiment influenced by recent developments in the securities industry [1][2]. Group 1: Securities Industry Developments - The Chairman of the China Securities Regulatory Commission, Wu Qing, emphasized the critical role of the securities industry during the "14th Five-Year Plan" period, outlining nine key requirements for the sector [2]. - Wu highlighted the securities industry as a major "service provider" for direct financing, an important "gatekeeper" for capital markets, and a professional "manager" of social wealth, indicating significant growth potential [2]. Group 2: Market Performance - Domestic brokerage stocks experienced a notable rise, with Hongye Futures (HK03678) increasing over 8%, and other firms like Guotai Junan (HK02611) and Huatai Securities (HK06886) rising more than 5% [2][4]. - The Hong Kong Securities ETF also saw an increase of over 3% in early trading [2]. Group 3: Sector Highlights - The Hang Seng Technology Index rose by 0.50% to 5,690.54 points, indicating a positive trend in technology stocks [3]. - Mixed performance was observed in the tech sector, with Baidu increasing over 4% and Meituan rising over 1%, while Lenovo saw a decline of 0.7% [6]. - Semiconductor stocks gained, with companies like SMIC and Hua Hong Semiconductor rising over 2% [6]. - The innovative drug sector showed strength, with Kangfang Biotech increasing over 2% [6]. - Domestic insurance stocks also performed well, with China Ping An and China Life both rising over 2% [6]. Group 4: Market Outlook - Huatai Securities noted that the recent appreciation of the RMB is a positive sign in domestic economic and financial data, suggesting that moderate appreciation could benefit corporate performance despite common beliefs about its negative impact on export companies [7]. - The firm indicated that the current market sentiment remains pessimistic, but it is viewed as a potential opportunity for investment, particularly in technology and pharmaceuticals, while also suggesting a focus on consumer goods for alpha opportunities [7].

国家医保局等部门印发《国家基本医疗保险、生育保险和工伤保险药品目录》以及《商业健康保险创新 药品目录》，自2026年1月1日起正式执行。 国家医保局成立以来医保药品目录已调整8次，本次医保药品目录调整新增114种药品，其中50种为1类 创新药。首版商保创新药目录共纳入19种药品，既有CAR-T等肿瘤治疗药品，也有社会关注度较高的阿 尔茨海默病治疗药品。 恒生医药ETF（159892）聚焦创新药产业，在港交所18A制度优势下覆盖众多创新标的（百济神州、信 达生物、康方生物等），有望受益于医保目录的更新和美联储降息。 （文章来源：每日经济新闻） 具体来看，复星医药的芦沃美替尼片进入2025年医保目录，北海康成的注射用维拉苷酶β进入商保创新 药目录。同时，5款CAR-T药进入商保创新药目录，分别是复星凯瑞的阿基仑赛注射液、药明巨诺的瑞 基奥仑赛注射液、合源生物的纳基奥仑赛注射液、驯鹿生物的伊基奥仑赛注射液、科济药业的泽沃基奥 仑赛注射液。 从药企角度来看，纳入医保+商保的创新药大多处于放量初期，随着政策红利释放，纳入医保、商保目 录的创新药有望快速放量。商保的逐步推广也有望增加创新药费用的支付来源，促进创新药在支付 ...

12月8日，港股开盘走势分化，其中恒生指数跌0.07%报26067.86点，恒生科技指数涨0.08%报5666.99 点，国企指数平开报919860点。红筹指数涨0.05%报4262.26点。 盘面上，大型科技股多数走低，腾讯控股跌0.41%，京东集团涨0.26%，小米集团涨0.33%，网易跌 0.09%，美团跌0.66%，快手跌0.65%，哔哩哔哩跌0.49%，百度涨3.29%；九方智投涨9.5%，创新药概念 多数上涨，康方生物涨超2%；中资券商股普遍上涨，华泰证券涨超3%；今日两只新股上市，卓越睿新 涨超23%，纳芯微平开。 世茂集团(00813.HK)：前11个月累计合约销售总额约224.32亿元，同比减少28.03%。 中梁控股(02772)前11个月合约销售额约112.2亿元，同比减少31.75% 时代中国控股(01233.HK)：前11个月累计合同销售金额约为47.87亿元，同比减少43.09%。 正荣地产(06158.HK)：前11个月累计合约销售金额约40.09亿元，同比减少33.07%。 喜相逢集团(02473.HK)：附属与哈啰租车签订业务合作协议 拟于指定城市以"联名店"模式开展汽车租赁 ...

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]